JP2012025767A5 - - Google Patents

Download PDF

Info

Publication number
JP2012025767A5
JP2012025767A5 JP2011215077A JP2011215077A JP2012025767A5 JP 2012025767 A5 JP2012025767 A5 JP 2012025767A5 JP 2011215077 A JP2011215077 A JP 2011215077A JP 2011215077 A JP2011215077 A JP 2011215077A JP 2012025767 A5 JP2012025767 A5 JP 2012025767A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
independently hydrogen
cancer cell
alkylhalo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011215077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012025767A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012025767A publication Critical patent/JP2012025767A/ja
Publication of JP2012025767A5 publication Critical patent/JP2012025767A5/ja
Pending legal-status Critical Current

Links

JP2011215077A 2003-06-25 2011-09-29 癌細胞におけるアポトーシスの誘導のための化合物および方法 Pending JP2012025767A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48288603P 2003-06-25 2003-06-25
US60/482,886 2003-06-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006517702A Division JP2007524633A (ja) 2003-06-25 2004-06-25 癌細胞におけるアポトーシスの誘導のための化合物および方法

Publications (2)

Publication Number Publication Date
JP2012025767A JP2012025767A (ja) 2012-02-09
JP2012025767A5 true JP2012025767A5 (enExample) 2013-01-10

Family

ID=34102647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006517702A Pending JP2007524633A (ja) 2003-06-25 2004-06-25 癌細胞におけるアポトーシスの誘導のための化合物および方法
JP2011215077A Pending JP2012025767A (ja) 2003-06-25 2011-09-29 癌細胞におけるアポトーシスの誘導のための化合物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006517702A Pending JP2007524633A (ja) 2003-06-25 2004-06-25 癌細胞におけるアポトーシスの誘導のための化合物および方法

Country Status (13)

Country Link
US (3) US7812058B2 (enExample)
EP (2) EP1653943B3 (enExample)
JP (2) JP2007524633A (enExample)
AT (2) ATE387911T1 (enExample)
AU (1) AU2004258867B2 (enExample)
CA (1) CA2529507C (enExample)
DE (2) DE602004012279T3 (enExample)
DK (1) DK1653943T4 (enExample)
ES (2) ES2303096T7 (enExample)
PL (1) PL1653943T6 (enExample)
PT (1) PT1653943E (enExample)
SI (1) SI1653943T1 (enExample)
WO (1) WO2005009434A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7354928B2 (en) * 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
PL1653943T6 (pl) 2003-06-25 2009-02-27 The Burnham Inst La Jolla Pochodne katecholu do leczenia raka
KR20080097496A (ko) * 2004-03-25 2008-11-05 더 리젠츠 오브 더 유니버시티 오브 미시간 고시폴 공결정 및 그의 용도
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
US7696372B2 (en) * 2007-10-01 2010-04-13 Ascenta Therapeutics, Inc. Process for preparing R-gossypol L-phenylalaninol dienamine
CN101896068A (zh) * 2007-10-19 2010-11-24 伯恩哈姆医学研究协会 抗凋亡蛋白的萘基抑制剂
FR2924712B1 (fr) 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
WO2010019914A2 (en) * 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
EP2418942B1 (en) 2009-04-15 2017-08-23 Sanford-Burnham Medical Research Institute Naphthalene-based inhibitors of anti-apoptotic proteins
US8772264B2 (en) 2009-08-04 2014-07-08 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
IN2012DN02816A (enExample) 2009-10-08 2015-07-24 Sanford Burnham Med Res Inst
WO2014127191A1 (en) 2013-02-15 2014-08-21 The Regents Of The University Of Michigan Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
RU2654711C1 (ru) * 2017-07-10 2018-05-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, обладающее апоптоз-индуцирующей активностью
CN115281419B (zh) * 2018-04-20 2024-11-05 耐克创新有限合伙公司 带有板和中间流体填充囊的鞋底结构及其制造方法
CN110128290B (zh) * 2019-05-10 2022-04-29 江苏耐雀生物工程技术有限公司 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用
CA3155694A1 (en) * 2019-09-24 2021-04-01 Genetec Inc. Intermediary device for daisy chain and tree configuration in hybrid data/power connection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
US5804567A (en) 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
AU2002230888A1 (en) * 2000-12-15 2002-06-24 Wackvom Limited Methods and compositions to treat conditions associated with neovascularization
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2002097053A2 (en) * 2001-05-30 2002-12-05 The Regents Of The University Of Michigan Small molecule antagonists of bcl2 family proteins
PL1653943T6 (pl) 2003-06-25 2009-02-27 The Burnham Inst La Jolla Pochodne katecholu do leczenia raka

Similar Documents

Publication Publication Date Title
JP2012025767A5 (enExample)
JP2012144574A5 (enExample)
PH12018501410A1 (en) Therapeutically active compounds and their method of use
JP2013542261A5 (enExample)
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
JP2013508347A5 (enExample)
WO2012009678A8 (en) Therapeutically active compositions and their method of use
JP2013534248A5 (enExample)
JP2013503846A5 (enExample)
JP2013532687A5 (enExample)
JP2011105738A5 (enExample)
MX350432B (es) Compuestos terapeuticamente activos y sus metodos de empleo.
JP2017524735A5 (enExample)
JP2011121989A5 (enExample)
JP2010519270A5 (enExample)
JP2013510120A5 (enExample)
IN2014CN00562A (enExample)
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
JP2014516033A5 (enExample)
JP2013532130A5 (enExample)
JP2012149068A5 (enExample)
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
JP2011037885A5 (enExample)
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
JP2015516419A5 (enExample)